0.97% -0.0099

Aytu Biopharma Inc (AYTU)

Überblick Nachrichten Preisverlauf Financials Warum fällt AYTU? Forum Prognose Aktiensplit

Schlusskurs vom Vortag:

24-Stunden-Volumen:

Relative Volume:

Marktkapitalisierung:

Nettoeinkommen (Verlust:

Netto-Cashflow:

1W Leistung:

1M Leistung:

6M Leistung:

1J Leistung:

1-Tages-Spanne:

1-Wochen-Bereich:

52-Wochen-Spanne:

Aytu Biopharma Inc Stock (AYTU) Company Profile

Aytu Biopharma Inc

Healthcare (1151)

(720) 437-6580

7900 E. UNION AVENUE, DENVER

@aytubioscience

Nächster Verdiensttermin

Neueste SEC-Einreichungen

AYTU's Discussions on Twitter

Vergleichen Sie AYTU mit anderen Aktien

Aktien	Preis	Marktkapitalisierung	Umsatz	Nettogewinn	Free Cashflow	ENV
AYTU Aytu Biopharma Inc	1.0101	6.17M	93.76M	-13.68M	8.77M	-2.63
ZTS Zoetis Inc	148.67	67.28B	9.26B	2.49B	2.30B	5.47
HLN Haleon Plc Adr	10.22	45.62B	14.35B	1.85B	0	0.4023
TAK Takeda Pharmaceutical Co Adr	14.71	45.01B	30.25B	1.37B	5.08B	0.4257
TEVA Teva Pharmaceutical Industries Ltd Adr	13.65	15.60B	16.54B	-1.64B	749.00M	-1.45
UTHR United Therapeutics Corp	284.73	12.77B	2.76B	1.11B	898.10M	22.77

Aytu Biopharma Inc Stock (AYTU) Upgrades & Downgrades

Datum	Aktion	Analytiker	Ratingänderung
2021-03-30	Eingeleitet	Cantor Fitzgerald	Overweight
2020-05-29	Eingeleitet	H.C. Wainwright	Buy

Aytu Biopharma Inc Aktie (AYTU) Neueste Nachrichten

Finanzdaten der Aytu Biopharma Inc-Aktie (AYTU)

Aytu Biopharma Inc (AYTU)

Aytu Biopharma Inc Stock (AYTU) Company Profile

Vergleichen Sie AYTU mit anderen Aktien

Aytu Biopharma Inc Stock (AYTU) Upgrades & Downgrades

Aytu Biopharma Inc Aktie (AYTU) Neueste Nachrichten

Aytu BioPharma, Inc. (NASDAQ:AYTU) On The Verge Of Breaking Even - simplywall.st

Aytu BioPharma Announces Closing of $4.0 Million Public Offering Priced At-the-Market - ACCESS Newswire

Aytu BioPharma Announces Pricing of $4.0 Million Public Offering Priced At-The-Market and the Appointment of a New Director - ACCESS Newswire

AYTU stock touches 52-week low at $1.13 amid market challenges - Investing.com India

Vascular Ehlers-Danlos Syndrome Market Growth Projections - openPR.com

Aytu BioPharma Strengthens Leadership Team with Appointment of Richard Eisenstadt as Chief Financial Officer - ACCESS Newswire

AYTU stock touches 52-week low at $1.2 amid market challenges - Investing.com Australia

AYTU BIOSCIENCE, INC : Entry into a Material Definitive Agreement, Unregistered Sale of Equity Securities, Change in Directors or Principal Officers, Financial Statements and Exhibits (form 8-K) - Marketscreener.com

AYTU stock touches 52-week low at $1.23 amid market challenges - Investing.com Australia

Insider Buying: Joshua Disbrow Acquires 15,000 Shares of Aytu Bi - GuruFocus.com

Aytu Biopharma CEO Joshua Disbrow buys $19,500 in stock - Investing.com India

Aytu Biopharma CEO Joshua Disbrow buys $19,500 in stock By Investing.com - Investing.com South Africa

AYTU BIOPHARMA CEO Acquires 15,000 Shares - TradingView

Aytu BioPharma Reports Second Quarter of Fiscal Year 2023 - ACCESS Newswire

Aytu BioPharma Regains Nasdaq Minimum Bid Price Compliance - ACCESS Newswire

Aytu BioPharma Reports Record Fourth Quarter and Fiscal Year 2022 Revenue - ACCESS Newswire

Earnings call transcript: Aytu BioPharma Q2 2025 sees revenue dip, strategic shifts - MSN

AYTU stock touches 52-week low at $1.3 amid market challenges - Investing.com Australia

AYTU stock touches 52-week low at $1.3 amid market challenges By Investing.com - Investing.com South Africa

Can This New Board Member Transform Evoke Pharma's Commercial Success? - StockTitan

Aytu BioScience and Neos Therapeutics Announce Special Meetings of Stockholders Related to Proposed Merger to Be Held on March 18, 2021 - ACCESS Newswire

Aytu BioPharma anticipates positive cash flow with ADHD growth and $2M annual cost savings - MSN

Aytu BioPharma Ranked Among Fastest-Growing Companies in North America on Deloitte's Technology Fast 500(TM) for Second Year in a Row - ACCESS Newswire

Aytu BioPharma’s Imminent Breakthrough: Can It Reach Profitability? - Mi Valle

Loss-Making Aytu BioPharma, Inc. (NASDAQ:AYTU) Set To Breakeven - Yahoo Finance

Aytu BioPharma Inc (AYTU) Q2 2025 Earnings Call Highlights: Stro - GuruFocus.com

Aytu BioScience Earnings Call: Growth Amid Challenges - TipRanks

Denver biotech cuts $500K check when it parted ways with its CFO - The Business Journals

Aytu BioPharma Inc (AYTU) Q2 2025 Earnings Call Highlights: Strong Cash Position and Strategic ... By GuruFocus - Investing.com Canada

Aytu BioPharma, Inc. (NASDAQ:AYTU) Q2 2025 Earnings Call Transcript - Insider Monkey

Aytu BioPharma Reports Strong Q2 Earnings Growth - TipRanks

Aytu BioPharma Inc. (AYTU) reports earnings - Quartz

AYTU BIOPHARMA, INC SEC 10-Q Report - TradingView

Aytu BioPharma Reports Fiscal 2025 Second Quarter Results - TradingView

Aytu BioPharma Reports Fiscal 2025 Second Quarter Operational and Financial Results - ACCESS Newswire

Aytu BioPharma Turns Profitable: Key Portfolio Growth Drives Q2 Transformation - StockTitan

Aytu BioPharma Reports First Quarter 2022 Financial Results - ACCESS Newswire

Aytu BioPharma to Report Fiscal 2025 Second Quarter Operational and Financial Results on February 12, 2025 - Galveston County Daily News

Aytu BioPharma Earnings Alert: Key Financial Results Coming February 12What to Watch - StockTitan

Aytu BioPharma to Report Fourth Quarter and Full Year Fiscal 2021 Results and Provide Business Update on September 27, 2021 - ACCESS Newswire

Aytu BioPharma to Present at LD Micro Main Event XVI Conference - ACCESS Newswire

Aytu BioPharma Announces Strategic Shift to Focus on Commercial Operations and Indefinite Suspension of Clinical Development Programs - ACCESS Newswire

Aytu BioPharma to Report Fiscal 2025 First Quarter Operational and Financial Results on November 13, 2024 - ACCESS Newswire

Aytu BioPharma to Participate in a Fireside Chat at the Lytham Partners 2024 Investor Select Conference on February 1, 2024 - ACCESS Newswire

Aytu BioPharma Reports Record ADHD Revenue and Operating Income During Fiscal 2024 Second Quarter - ACCESS Newswire

Aytu BioPharma Announces Initiation of the AR101 PREVEnt Trial for the Treatment of Vascular Ehlers-Danlos Syndrome - ACCESS Newswire

Aytu BioPharma Ranked as One of Fastest-Growing Companies in North America on the 2024 Deloitte Technology Fast 500(TM) - ACCESS Newswire

Aytu BioPharma Announces the Passing of Co-Founder and Board Member Michael Macaluso - ACCESS Newswire

Aytu BioPharma Ranked Among Fastest-Growing Companies in North America on Deloitte's Technology Fast 500(TM) for Third Consecutive Year - ACCESS Newswire

Aytu BioPharma to Participate in the Lytham Partners 2025 Investor Healthcare Summit on January 13, 2025 - ACCESS Newswire

Aytu BioPharma Announces Exclusive Agreement with Lupin Pharma Canada Ltd to Commercialize Adzenys XR-ODT(R) and Cotempla XR-ODT(R) in Canada - ACCESS Newswire

Finanzdaten der Aytu Biopharma Inc-Aktie (AYTU)

Umsatz

Nettogewinn

Free Cashflow

ENV

Ähnlich wie AYTU